|

The Sequencing for Detection in Congenital Heart Disease (SD-CHD) Study

RECRUITINGN/ASponsored by Scripps Translational Science Institute
Actively Recruiting
PhaseN/A
SponsorScripps Translational Science Institute
Started2024-01-09
Est. completion2026-04-01
Eligibility
Age18 Years+
SexFEMALE
Healthy vol.Accepted
Locations1 site

Summary

This study is enrolling pregnant persons treated at Rady Children's Hospital fetal cardiology program with a prenatal diagnosis of congenital heart disease to look for genetic disorders in the fetus or unborn baby. Congenital heart disease (CHD) is a group of structural differences to the heart that represent the most common birth defect among liveborn infants world-wide. CHD is the leading cause of birth-defect associated infant death. Prenatal detection allows for delivery planning, postnatal repair, specialized medications, and detailed counseling for parents. Up to one in three fetuses with CHD may have a genetic cause. In babies, knowing about genetic diseases helps patients and doctors provide the best care for their babies. If identified prenatally, this same knowledge may help participants prepare for their location of delivery, meet with specialists, and consider specialized treatments and medications that may be appropriate. The diagnostic yield and clinical utility of whole genome sequencing (WGS) in fetuses with prenatally detected congenital heart disease (CHD) will be compared to routine clinical testing in patients choosing amniocentesis or chorionic villus sampling. DNA will be obtained from fetal samples and biological parent blood samples and analyzed according to standard clinical interpretation guidelines. Results will be reported to healthcare providers and patients and measures of clinical utility will be collected. Additionally, measures of stress, anxiety, depression, and perceived utility of information will be assessed by validated survey tools. A historical cohort of patients electing for diagnostic procedures will be used as a comparison population.

Eligibility

Age: 18 Years+Sex: FEMALEHealthy volunteers accepted
Inclusion Criteria:

* Pregnant individual with ongoing pregnancy with prenatally detected fetal CHD
* Desire for genetic diagnosis and clinical plan for amniocentesis or chorionic villus sampling

Exclusion Criteria:

* Gestational age of 38 weeks or greater
* Clinical course entirely explained by known chromosomal abnormality or confirmed genetic diagnosis that explains the clinical condition
* Pregnant persons under 18 years of age

Conditions2

Congenital Heart DiseaseHeart Disease

Locations1 site

Rady Children's Institute for Genomic Medicine
San Diego, California, 92123
Rebecca Reimers, MD/MPH858-494-5290

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.